Abzu

Supporting critical decision-making in pharma R&D.

decisionmaking brainstorming solutions

Tool Information

Primary Task	Decision making
Category	business-and-finance
Sub Categories	business-intelligence project-management
Country	Denmark
Industry	research
Technologies	Gmail, Google Apps, Microsoft Office 365, CloudFlare Hosting, Netlify, React, DigitalOcean, Mobile Friendly, WordPress.org, Google Font API, Remote, AI
Website Status	🟢 Active

Abzu AI is a trustworthy and rational AI tool designed to assist in mission-critical decision-making processes. The platform offers rational and evidence-based decision support for various operations. In the field of pharmaceutical research and development, Abzu AI helps reduce the time, expense, and complexity of drug development. The tool is backed by a proven team, advanced technology, and demonstrated results.Abzu AI has gained recognition and trust from several prominent organizations and institutions. Peptomyc, Roche, Singleron, Sirana Pharma, SSI - Statens Serum Institut, ALK Abello, Checkmate Pharma, COV-IRT, Trackunit, and NASA GeneLab are among the companies and institutions that rely on Abzu AI for trustworthy and rational decision-making processes.While specific details about the functionalities and technical aspects of the tool are not provided, Abzu AI is presented as a solution that supports critical decision-making in a range of areas, including transportation and logistics, healthcare operations, disease understanding, RNA therapeutics, and bioinformatics services.The description emphasizes the reliability and efficiency of Abzu AI in improving decision-making outcomes, enabling users to make better and faster decisions. It is important to note that pricing information is not included in the description. To learn more about the features and capabilities of Abzu AI, interested individuals can visit the provided website.

Abzu is a deep tech startup founded in January 2018, based in Copenhagen, Denmark, with additional offices in Barcelona, Spain. The company focuses on developing explainable artificial intelligence (AI) to enhance drug discovery and lower research and development costs in the pharmaceutical and biotech industries.

Abzu's flagship technology, QLattice, is an AI simulator that explores all possible relationships within data. This innovative tool helps identify the most significant connections, facilitating a deeper understanding of diseases and accelerating the drug development process. The company provides comprehensive services for drug design and in vitro validation, ensuring high-quality data for AI and machine learning models. Abzu aims to support pharmaceutical and biotech companies in streamlining their drug discovery efforts.

With a mission to empower scientists, Abzu fosters a culture of self-management, transparency, and trust, encouraging creative and collaborative work. The company has raised $7.92 million in funding, positioning itself as a leader in AI-driven solutions for drug design and disease understanding.